HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Multiple primary malignant tumors in patients with Hodgkin’s lymphoma

DOI: https://doi.org/10.29296/25877305-2019-11-01
Issue: 
11
Year: 
2019

S. Shakhtatina(1), MD; A. Danilenko(1), MD; N. Falaleeva(1), MD; S. Ivanov(1), MD; Professor A. Kaprin(2), MD, Academician of the Russian Academy of Sciences 1-A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk 2-National Medical Radiology Research Center, Moscow

The presence of ≥2 malignant neoplasms of different genesis in a patient is considered as a multiple primary malignant tumor. Hodgkin’s lymphoma (HL) is recognized as a potentially treatable disease. The increase in the life expectancy of patients necessitates an examination of 2 (metachronous) malignant tumors in these patients. The incidence of metachronous malignant tumors in patients with HL is higher than that in the population, which should be taken into account during a follow-up.

Keywords: 
oncology
Hodgkin’s lymphoma
metachronous malignant tumor
relative risk



References: 
  1. Zlokachestvennye novoobrazovanija v Rossii v 2017 g. (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj / M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018; 250 s. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Edited by A.D. Kaprina, V.V. Starinsky, G.V. Petrova / M.: Moscow them. P.A. Herzen – a branch of the Federal Research Center of Radiology Research Center of the Ministry of Health of Russia, 2018; 250 p. (in Russ.)].
  2. Davydov M.I., Aksel' E.M. Statistika zlokachestvennyh zabolevanij v Rossii i stranah SNG v 2008 g. // Vestnik RONTs im. Blohina RAMN. – 2010; 21 (2, pril. 1): 52–9 [Davydov M.I., Axel E.M. Statistics of malignant diseases in Russia and the CIS countries in 2008 // Vestnik RONTs im. Blokhina RAMN. – 2010; 21 (2, suppl. 1): 52–9 (in Russ.)].
  3. Vanderbroucke J. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio // Am. J. Epidemiol. – 1982; 115: 303–4.
  4. Danilenko A.A., Shahtarina S.V. Limfoma Hodzhkina i vtorye zlokachestvennye opuholi // Vopr. onkol. – 2009; 55 (6): 692–702 [Danilenko A.A., Shakhtarina S.V. Hodgkin’s lymphoma and second malignant tumors // Vopr. onkol. – 2009; 55 (6): 692–702 (in Russ.)].
  5. Shakhtarina, S., Danilenko A., Pavlov V. Second cancer risks in patients with supradiaphragmatic Hodgkin lymphoma // Haematologica. – 2016; 101 (Suppl. 5): 71.
  6. Kumar V., Mohit G., Chandra Ad. et al. Trends in the risks of secondary cancers in patients with Hodgkin Lymphoma // Clinical Lymphoma, Myeloma & Leukemia. – 2018; 18 (9): 576–89.
  7. Von Tresckow B., Kreissl S., Goergen H. et al. Intensive treatment strategies in advanced-stage Hodgkin`s lumphoma (HD 9 and HD 12): analisis of long-term survival in two randomized trials // Lancet Haematol. – 2018; 10: e462–e473. DOI: 10.1016/S2352-3026(18)30140-6.
  8. Wolden S., Hancock S., Carlson R. et al. Management of breast cancer after Hodgkin’s disease // J. Clin. Oncol. – 2000; 18: 765–72.
  9. Ibrahim E., Abouelkhair K., Kazkaz G. et al .Risk of second breast cancer in female Hodgkin`s Lymphoma survivors: a meta-analysis // BMC Cancer. – 2012; 12: 197. http://doi.org/10.1186/1471-2407-12-197.
  10. Koh E., Trun T., Heydarian M. A comparison of mantle versus involved-field radiotherapy for Hodgkin`s Lymphoma: reduction an normal tissue dose and second cancer risk // Radiation Oncology. – 2007; 2: 13. http://doi.org/10.1186/1748-717X-2-13.
  11. Journi N., Mansouri I., Allodji R. et. al. Volume effects of radiotherapy on the risk of secondary primary cancers: A systematic review of clinical and epidemiological studies // Radiother. Oncol. – 2018; pii: S0167–8140(18)33500-X. DOI: 10.1016/j.radonc.2018.09.017.
  12. Travis L., Gospodarowicz M., Curtis R. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease // J. Nat. Cancer Inst. – 2002; 94 (3): 182–92.
  13. Shahtarina S.V., Danilenko A.A., Pavlov V.V. i dr. Vlijanie protivoopuholevoj lekarstvennoj i luchevoj terapii na sostojanie schitovidnoj zhelezy u bol'nyh limfomoj Hodzhkina v otdalennye sroki nabljudenija // Klin. onkogematol. – 2014; 7 (4): 533–9 [Shakhtarina S.V., Danilenko A.A., Pavlov V.V. et al. Influence of antitumor drug and radiation therapy on the state of the thyroid gland in patients with Hodgkin’s lymphoma in the long-term follow-up period // Clin. Oncohematol. – 2014; 7 (4): 533–9 (in Russ.)].
  14. Kaprin A.D., Galkin V.N., Zhavoronkov L.P. i dr. Sintez fundamental'nyh i prikladnyh issledovanij – osnova obespechenija vysokogo urovnja nauchnyh rezul'tatov i vnedrenija ih v meditsinskuju praktiku // Radiatsija i risk. – 2017; 26 (2): 26–40 [Kaprin A.D., Galkin V.N., Zhavoronkov L.P. et al. Synthesis ofbasic and applied research is the basis ofobtaining high-quality findingsand translatingthem intoclinicalpractice // Radiation and risk. – 2017; 26 (2): 26–40 (in Russ.)].